XORTX Therapeutics Inc.
XRTX
$0.60
-$0.03-4.20%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -2.62% | 16.21% | |||
| Depreciation & Amortization | 6.15% | -0.38% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -12.72% | 74.04% | |||
| Operating Income | 12.72% | -74.04% | |||
| Income Before Tax | -2.72% | -670.37% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -2.72% | -670.37% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2.72% | -670.37% | |||
| EBIT | 12.72% | -74.04% | |||
| EBITDA | 12.89% | 3.79% | |||
| EPS Basic | -1.34% | -600.00% | |||
| Normalized Basic EPS | -1.37% | -599.15% | |||
| EPS Diluted | 0.00% | -609.38% | |||
| Normalized Diluted EPS | -1.37% | -599.15% | |||
| Average Basic Shares Outstanding | 1.37% | 14.08% | |||
| Average Diluted Shares Outstanding | 1.37% | 14.08% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||